Literature DB >> 26483203

JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.

Wenyi Sun1, Zuoquan Xie1, Yifu Liu2, Dan Zhao3, Zhixiang Wu4, Dadong Zhang1, Hao Lv1, Shuai Tang1, Nan Jin1, Hualiang Jiang3, Minjia Tan4, Jian Ding1, Cheng Luo5, Jian Li6, Min Huang7, Meiyu Geng7.   

Abstract

Pyruvate dehydrogenase kinase PDK1 is a metabolic enzyme responsible for switching glucose metabolism from mitochondrial oxidation to aerobic glycolysis in cancer cells, a general hallmark of malignancy termed the Warburg effect. Herein we report the identification of JX06 as a selective covalent inhibitor of PDK1 in cells. JX06 forms a disulfide bond with the thiol group of a conserved cysteine residue (C240) based on recognition of a hydrophobic pocket adjacent to the ATP pocket of the PDK1 enzyme. Our investigations of JX06 mechanism suggested that covalent modification at C240 induced conformational changes at Arginine 286 through Van der Waals forces, thereby hindering access of ATP to its binding pocket and in turn impairing PDK1 enzymatic activity. Notably, cells with a higher dependency on glycolysis were more sensitive to PDK1 inhibition, reflecting a metabolic shift that promoted cellular oxidative stress and apoptosis. Our findings offer new mechanistic insights including how to therapeutically target PDK1 by covalently modifying the C240 residue. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26483203     DOI: 10.1158/0008-5472.CAN-15-1023

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors.

Authors:  Shih-Chia Tso; Mingliang Lou; Cheng-Yang Wu; Wen-Jun Gui; Jacinta L Chuang; Lorraine K Morlock; Noelle S Williams; R Max Wynn; Xiangbing Qi; David T Chuang
Journal:  J Med Chem       Date:  2017-01-31       Impact factor: 7.446

2.  Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met.

Authors:  Lei Wang; Mingzhao Gao; Mengya Tong; Chengying Xie; Ye He; Li Fu; Yun Li; Haoyu Fu; Liguang Lou
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis.

Authors:  G Li; M Li; J Hu; R Lei; H Xiong; H Ji; H Yin; Q Wei; G Hu
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

4.  Increased pyruvate dehydrogenase activity in skeletal muscle of growth-restricted ovine fetuses.

Authors:  Alexander L Pendleton; Laurel R Humphreys; Melissa A Davis; Leticia E Camacho; Miranda J Anderson; Sean W Limesand
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-07-17       Impact factor: 3.619

5.  Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L.

Authors:  Ittipat Meewan; Jacob Kattoula; Julius Y Kattoula; Danielle Skinner; Pavla Fajtová; Miriam A Giardini; Brendon Woodworth; James H McKerrow; Jair Lage de Siqueira-Neto; Anthony J O'Donoghue; Ruben Abagyan
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-13

6.  Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.

Authors:  Thanigaimalai Pillaiyar; Philipp Flury; Nadine Krüger; Haixia Su; Laura Schäkel; Elany Barbosa Da Silva; Olga Eppler; Thales Kronenberger; Tianqing Nie; Stephanie Luedtke; Cheila Rocha; Katharina Sylvester; Marvin R I Petry; James H McKerrow; Antti Poso; Stefan Pöhlmann; Michael Gütschow; Anthony J O'Donoghue; Yechun Xu; Christa E Müller; Stefan A Laufer
Journal:  J Med Chem       Date:  2022-06-16       Impact factor: 8.039

7.  Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.

Authors:  Wenjia Zhang; Jing Su; Huadan Xu; Shanshan Yu; Yanan Liu; Yong Zhang; Liankun Sun; Ying Yue; Xiaoli Zhou
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

8.  Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.

Authors:  Huadan Xu; Yichun He; Jiaoyan Ma; Yuanxin Zhao; Yanan Liu; Liankun Sun; Jing Su
Journal:  Int J Oncol       Date:  2020-07-10       Impact factor: 5.650

9.  Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases.

Authors:  Xiaoli Zhou; Shanshan Yu; Jing Su; Liankun Sun
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

10.  α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells.

Authors:  Liduo Yue; Yanbei Ren; Qingxi Yue; Zhou Ding; Kai Wang; Tiansheng Zheng; Guojie Chen; Xiangyun Chen; Ming Li; Lihong Fan
Journal:  Oxid Med Cell Longev       Date:  2021-06-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.